|
|
1. MARKET OVERVIEW
|
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
Cancer/Tumor Profiling: Market Overview & Outlook |
Cancer/Tumor Profiling – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS
|
3. MARKET TRENDS & DRIVERS
|
Increasing Incidence of Cancer Worldwide: Primary Growth Driver |
EXHIBIT: Cancer Rates (100,000 People) in Select Countries: 2021 |
EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020 |
EXHIBIT: Estimated Number of New Cancer Cases in Men by Cancer Type: 2020 |
The United States: Characterized by Higher Incidence of Cancer |
EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020 |
EXHIBIT: Estimated New Cases for Selected Cancers in the US by State: 2020 |
Enhanced Use of Biomarkers in Tumor Profiling Bodes Well |
Cancer Research & Funding Initiatives Augment Market Prospects |
Growing Role of Personalized Medicine Augurs Well |
Advances in Point-of-Care Cancer Diagnostics to Accelerate Uptake |
4. GLOBAL MARKET PERSPECTIVE
|
World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Cancer / Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Cancer / Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Cancer / Tumor Profiling Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
|
UNITED STATES
|
Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
CANADA
|
Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
JAPAN
|
Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
CHINA
|
Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
EUROPE
|
Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
Europe Historic Review for Cancer / Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Cancer / Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
FRANCE
|
Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
GERMANY
|
Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
ITALY
|
Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
UNITED KINGDOM
|
Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
REST OF EUROPE
|
Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
ASIA-PACIFIC
|
Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
REST OF WORLD
|
Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of World 16-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2014, 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of World 16-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2014, 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Clinical and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World Historic Review for Cancer / Tumor Profiling by Application - Clinical and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of World 16-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical and Research for the Years 2014, 2023 & 2030 |
|
|